If you are to succeed in commercializing a medical device, you need a clear path to reimbursement. However, the path is often nonintuitive, and increasing globalization has complicated matters. Payers now reference prices from around the world and employ health economics and cost containment tools first seen in pharma. Some companies have adapted by seeking revenue for services beyond the physical product. Join us to get the full briefing from Ali Samiian, Global Head of Market Access, Health Economics and Pricing at Abbott Diabetes Care.
Where & When
5:30 to 6:30 PM, Tuesday, February 5, 2019
Room 212, Byers Hall, UCSF Mission Bay (1700 4th St., San Francisco)
About the Speaker
A lawyer by training, Ali has worked in government in the healthcare sector providing policy advice to the Minister of Health in Ontario, Canada on Pharmaceuticals, Diagnostic devices, and physician negotiations. He has over 10 years of experience working in the pharmaceutical and medical device sector in several roles of increasing responsibility, including market access, sales, and strategic planning in global, regional and country affiliate organizations. He has launched products in Canada, Europe, US and several Asia Pac markets.
Ali holds a JD from Osgoode Hall Law School, an MBA from the Schulich School of Business in Canada, and a MSc in Health Economics, Policy and Management from the London School of Economics.
He is currently the global head of Market Access, Health Economics and Pricing at Abbott Diabetes Care, managing a team to ensure global reimbursement of a new glucose sensing category. He is a proud husband and father of 2.